Obesity and hypertension

Endocrinology and Metabolism Clinics of North America

Volumn 32, Issue 4, 2003, Pages 823-854

  El Atat, Fadi ^a   Aneja, Ashish ^a   Mcfarlane, Samy ^a   Sowers, James ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOBESITY AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIUM DERIVED RELAXING FACTOR; FATTY ACID; HYDROCORTISONE; LEPTIN; MELANIN CONCENTRATING HORMONE; NATRIURETIC PEPTIDE TYPE C; NEUROPEPTIDE Y; NITRIC OXIDE; OREXIN; PROOPIOMELANOCORTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT;

ADIPOSE TISSUE; ADRENERGIC SYSTEM; ANIMAL MODEL; BEHAVIOR MODIFICATION; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; EXERCISE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KIDNEY TUBULE FUNCTION; MEAN ARTERIAL PRESSURE; META ANALYSIS; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOSIS; TREATMENT OUTCOME;

AGOUTI; ANIMALIA; GLOMERULUS; PIERINAE;

EID: 0347993842     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(03)00070-7     Document Type: Review

References (197)

1. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001;14:103S-15S.
2. Mark AL, Correia M, Morgan DA, et al. State-of-the-art-lecture: obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 1999;3:537-41.
3. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002;324:127-37.
4. Castro JP, El-Atat FA, McFarlane SI, et al. Cardiometabolic syndome: pathophysiology and treatment. Curr Hypertens Rep 2003;5:393-401.
5. Zhang R, Reisin E. Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens 2000;13:1308-14.
6. Kumanyika S. Obesity in black women. Epidemiol Rev 1987;9:31-50.
7. Garrison RJ, Kannel WB, Stokes J, et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987;16:234-51.
8. Reavan GM. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med 1993;44:121-31.
9. Landsberg L. Insulin and hypertension: lessons from obesity. N Engl J Med 1987;317:378-9.
10. Engeli S, Sharma AM. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol 2002;17:355-9.
11. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:761-811.
12. Rocchini AP. Obesity hypertension. Am J Hypertens 2002;15:50S-2S.
13. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 1997;10:49S-55S.
14. Loredo JS, Ancoli-Israel S, Dimsdale JE. Sleep quality and blood pressure dipping in obstructive sleep apnea. Am J Hypertens 2001;14:887-92.
15. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001;79:21-9.
16. Berchtold P, Jorgens V, Finke C, et al. Epidemiology of obesity and hypertension. Int J Obes 1981;5:1-7.
17. Weyer C, Pratley RE, Snitker S, et al. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000;36:531-7.
18. Abate NI, Mansour YH, Arbique D, et al. Overweight and sympathetic activity in black Americans. Hypertension 2001;38:379-83.
19. Hall JE, Brands MW, Dixon WN, et al. Obesity-induced hypertension: renal function and systemic hemodynamics. Hypertension 1993;22:292-9.
20. Carrol JF, Huang M, Hester RL, et al. Hemodynamic alterations in obese rabbits. Hypertension 1995;26:465-70.
21. Rocchini AP, Mao HZ, Babu K, et al. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension 1999;33:548-53.
22. Hall JE, Zappe DH, Alonso-Galicia M, et al. Mechanisms of obesity-induced hypertension. News Physiol Sci 1996;11:255-61.
23. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep 2000;11:139-47.
24. Van Vliet BN, Hall JE, Mizelle HL, et al. Reduced parasympathetic control of heart rate in obese dogs. Am J Physiol 1995;269:H629-37.
25. Antic V, Kiener-Belforti F, Tempini A, et al. Role of the sympathetic nervous system during the development of obesity hypertension in rabbits. Am J Hypertens 2000;13:556-9.
26. Jones DW, Kim JS, Andrew ME, et al. Body mass index and blood pressures in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 1994;12:1433-7.
27. Cignolini M, Seidell JC, Targher JP, et al. Fasting serum insulin in relation to components of the metabolic syndrome in European healthy men: the European fat distribution study. Metabolism 1995;44:35-40.
28. Dobrian AD, Davies MJ, Prewitt RL, et al. Development of a rat model of diet-induced obesity. Hypertension 2000;35:1009-15.
29. Alexander J, Dustan HP, Sims EAH, et al. Report of the Hypertension Task Force. Washington, DC: US Government Printing Office; 1979. US Department of Health, Education, and Welfare, Publication #NIH 70-1631.
30. Reisen E, Abel R, Modan M, et al. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978;198:1-6.
31. Burt V, Cutler JA, Higgins M, et al. NHANES II and III. Hypertension 1995;26:60-9.
32. Rocchini AP, Key J, Bordie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989;321:580-5.
33. Tuck ML, Sowers J, Dornfield L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure plasma renin activity and plasma aldosterone level in obese patients. N Engl J Med 1981;304:930-3.
34. Landsberg L, Krieger DR. Obesity, metabolism, and the sympathetic nervous system. Am J Hypertens 1989;2:1255-325.
35. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 1999;892:91-107.
36. Stern JS, Gades MD, Wheeldon CM, et al. Calorie restriction in obesity: prevention of kidney disease in rodents. J Nutr 2001;131:913S-7S.
37. Reisin E, Azars S, DeBoisblanc BP, et al. Low calorie unrestricted protein diet attenuates renal injury in hypertensive rats. Hypertension 1993;21:971-4.
38. US Renal Data System. USRDS 2001 annual data report: atlas of end-stage renal disease in the United States. Bethesda. MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: 2001.
39. Pugh JA, Medina RA, Cornell JC, et al. NIDDM is the major cause of end-stage renal disease. More evidence from a tri-ethnic population. Diabetes 1995;44:1375-80.
40. Kassab S, Kato T, Wilkins C, et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995;25:893-7.
41. Baron AD, Steinberg HO, Chaker H. Insulin mediated skeletal muscle vasodilation contributed to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995;96:786-92.
42. Hall JE, Zappe DH, Alonso-Galicia A, et al. Renal pathophysiology in obesity-induced hypertension. News Physiol Sci 1996;11:255-61.
43. Reaven GM, Hoffman BB. A role for insulin in the etiology and course of hypertension. Lancet 1987;2:435-7.
44. Tuck ML. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992;19:167-77.
45. Lucas CP, Estigarribia JA, Darga LL, et al. Insulin and blood pressure. Hypertension 1985;7:702-6.
46. Sugarman HJ, Windsor ACJ, Bessos MK, et al. Intra-abdominal pressure, sagittal abdominal diameter and obesity co-morbidity. J Intern Med 1997;241:71-9.
47. Bloomfield GL, Sugerman HJ, Blocher CR, et al. Chronically increased intra-abdominal pressure produced systemic hypertension in dogs. Int J Obes Relat Metab Disord 2000;24:819-24.
48. Sundquist J, Winkeby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: An analysis of NHANES III: 1988-1994. J Am Geriatr Soc 2001;49:109-16.
49. Okosun ISA, Choi S, Dent MM, et al. Abdominal obesity defined as a larger than expected girth is associated with racial/ethnic differences in the risk of hypertension. J Hum Hypertens 2001;15:307-12.
50. Wesson DE, Kurtzman NA, Prommer JP. Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron 1985;40:235-7.
51. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12:1211-7.
52. Weisinger JR, Kempson RL, Eldridge L, et al. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 1974;81:440-7.
53. Kambham N, Markowitz GS, Valeri AM, et al. Obesity related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-509.
54. Hall JE, Brands MW, Henegar JR, et al. Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol 1998;25:58-64.
55. Hall JE. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994;23:381-94.
56. Alonso-Galicia M, Dwyer TM, Herrera GA, et al. Increased hyaluronic acid in the inner medulla of obese dogs. Hypertension 1995;25:888-92.
57. Arnold MD, Brissie R, Soonz JS, et al. Obesity associated renal medullary changes [abstract]. Lab Invest 1994;70:156A.
58. Reisin E, Messerli FG, Ventura HO, et al. Renal hemodynamics in obese and lean essential hypertensive patients. J Hypertens 1987;5:397-400.
59. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda, MD: National Heart, Lung, and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases; 1998. Publication #NIH 98-4083.
60. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: Prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47.
61. Rumantir MS, Vaz M, Jennings GL, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999;17:1125-33.
62. Mansuo K, Mikami H, Ogihara T, et al. Weight gain-induced blood pressure elevation. Hypertension 2000;35:1135-40.
63. Grassi G, Servalle G, Cattaneo BM, et al. Sympathetic activity in obese normotensive subjects. Hypertension 1995;25:560-3.
64. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000;13:99s-105s.
65. Grassi G, Seravalle G, Columbo M, et al. Body weight reduction sympathetic nerve traffic and arterial baroreflex in obese normotensive humans. Circulation 1998;97:2037-42.
66. Weyer C, Pratley RE, Snitker S, et al. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000;36:531-7.
67. Hall JE, Van Vliet BN, Garrity CA, et al. Obesity hypertension: role of adrenergic mechanisms. Hypertension 1993;21:528.
68. Hildebrandt DA, Mizelle HL, Brands MW, et al. Systemic hemodynamic actions of long-term intravertebral angiotensin II infusion. FASEB J 1993;7: A405 [abstract].
69. Wofford MR, Anderson DC, Brown CA, et al. Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001;14:694-8.
70. Hall JE, Van Vliet BN, Gamty CA, et al. Role of increased adrenergic activity in obesity-induced hypertension. Circulation 1992;86:I.
71. Licata G, Volpe M, Scaglione R, et al. Salt-regulating hormones in young normotensive obese subjects: effects of saline load. Hypertension 1994:23(Suppl 1):120-4.
72. Hall JE. Hyperinsulinemia: a link between obesity and hypertension? Kidney Int 1993;43:1402-17.
73. Rocchini A, Marker P, Cervenka T. Time course of insulin resistance associated with weight gain in the dog: relationship to the development of hypertension. Am J Physiol 1996;272:E147-54.
74. DeFronzo RA, Cooke CR, Andres R, et al. The effect of insulin on renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 1975;55:845-55.
75. Rocchini AP, Moorehead C, DeRemer S, et al. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension 1990;15:861-6.
76. Hall JE, Granger JP, Hester RL, Montani JP. Mechanisms of sodium balance in hypertension: role of pressure natriuresis. J Hypertens 1986;4:S57-65.
77. Rocchini AP, Moorehead C, Wentz E, et al. Obesity-induced hypertension in the dog. Hypertension 1987;9(6 Pt 2):III64-8.
78. Rocchini AP, Katch V, Kveselis D, et al. Insulin and renal retention in obese adolescents. Hypertension 1989;14:367-74.
79. Sechi LA. Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. J Hypertens 1999;17:1229-37.
80. Hall JE, Brands MW, Zappe DH, et al. Hemodynamic and renal responses to chronic hyperinsulinemia in obese, insulin resistant dogs. Hypertension 1995;25:994-1002.
81. Hildebrandt DA, Smith MJ Jr, Hall JE. Cardiovascular regulation during acute and chronic vertebral artery insulin infusion in concious dogs. J Hypertens 1999;17:252-60.
82. Brands MW, Harrison DL, Keen HL, et al. Insulin-induced hypertension in rats is dependent on an intact renin-angiotensin system. Hypertension 1997;29:1014-9.
83. Keen HL, Brands MW, Smith MS Jr, et al. Inhibition of thromboxane synthesis attenuates insulin-hypertension in rats. Am J Hypertens 1997;10:1125-31.
84. Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Intern J Obes Relat Metab Dis 2000;24:S80-5.
85. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956;4:20-34.
86. Rosmond R, Chagnon YC, Holm G, et al. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes Res 2000;8:211-8.
87. Stepniakowski KT, Goodfriend TL, Egan BM. Fatty acids enhance vascular α-adrenergic sensitivity. Hypertension 1995;25:774-8.
88. Grekin RJ, Dumont CJ, Vollmer AP, et al. Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion. Am J Physiol 1997;273:R324-30.
89. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997;100:1230-9.
90. Hildebrandt DA, Kirk D, Hall JE. Renal and cardiovascular responses to chronic increases in cerebrovascular free fatty acids. FASEB J 1999;13:A780.
91. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998;31:409-14.
92. Stamler J. Epidemic obesity in the United States. Arch Intern Med 1993;153:1040-4.
93. Zhjang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
94. Mark AL, Shaffer RA, Correia ML, et al. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow mice. J Hypertens 1999;17:1949-53.
95. Haynes WG, Morgan DA, Walsh SA, et al. Cardiovascular consequences of obesity: role of leptin. Clin Exp Pharmacol Physiol 1998;25:65-9.
96. Haynes WG, Sivitz WI, Morgan DA, et al. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30:619-23.
97. Casto RM, VanNess JM, Overton JM. Effects of central leptin administration on blood pressure in normotensive rats. Neurosci Lett 1998;246:29-32.
98. Lembo G, Vecchione C, Fratta L, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000;49:293-7.
99. Flier JS, Maratos-Flier E. Obesity and the hypothalamus: novel peptides for new pathways. Cell 1998;92:437-40.
100. McAuley MA, Chen X, Westfall TC. Central cardiovascular actions of neuropeptide Y. In: Colmers WF, Wahlestedt C, editors. The biology of neuropeptide Y and related peptides. Totowa, NJ: Humana Press; 1993. p. 389-418.
101. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997;88:131-41.
102. Fan W, Boston BA, Kesterson RA, et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997;385:165-8.
103. Thornton JE, Chueng CC, Clifton DK, et al. Regulation of hypothalamic proopio-melanocortin mRNA by leptin in ob/ob mice. Nature 1994;372:425-32.
104. Haynes WG, Morgan DA, Djalali A, et al. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999;33:542-7.
105. Aizawa-Abe M, Ogawa Y, Mazuzaki H, et al. Pathophysiological role of leptin in obesity related hypertension. J Clin Invest 2000;105:1243-52.
106. Shirasaka T, Bnakazato M, Matsukura S, et al. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol 1999;177:R1780-5.
107. Sakurai T. Orexins and orexin receptors: implications in feeding behaviour. Regul Pept 1999;85:25-30.
108. Shek EW, Kim PK, Hall JE. Adrenergic blockade prevents leptin-induced hypertension. FASEB J 1999;13:A456.
109. El-Haschimi K, Pierroz DD, Hileman SM, et al. Two defects contribute to hypothalmic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000;105:1827-32.
110. Ishizuka T, Ernsberger P, Liu S, et al. Phenotypic consequences of a nonsense mutation in the leptin receptor gene (fak) in obese spontaneously hypertensive Koletsky rats. J Nutr 1998;128:2299-306.
111. VanHeek M, Comptom DS, France CF, et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997;99:385-90.
112. Lu H, Duanmu Z, Houck C, Jen KL, et al. Obesity due to high fat diet decreases the sympathetic nervous and cardiovascular responses to intracerebroventricular leptin in rats. Brain Res Bull 1998;47:331-5.
113. Frubeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999;48:903-8.
114. Kuo J, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001;37:670-6.
115. Hirose H, Saito I, Tsujioka M, et al. The obese gene product, leptin: possible role in obesity-related hypertension in adolescents. J Hypertens 1998;16:2007-12.
116. Suter PM, Locher R, Häsler E, et al. Is there a role for the ob gene product leptin in essential hypertension? Am J Hypertens 1998;11:1305-11.
117. Onions KL, Hunt SC, Rutkowski MP, et al. Genetic markers at the leptin (ob) locus are not significantly linked to hypertension in African Americans. Hypertension 1998;31:1230-4.
118. Hall JE, Shek EW, Brands MW. Is leptin a link between obesity and hypertension? Curr Opin Endocrinol Diabetes 1999;6:225-9.
119. Carlyle M, Jones OB, Kuo JJ, et al. Chronic cardiovascular and renal actions of leptin - role of adrenergic activity. Hypertension 2002;39:496-501.
120. Rahmouni K, Haynes WG, Morgan DA, et al. Selective resistance to central administration of leptin in agouti mice [abstract]. Hypertension 2001;38:506.
121. Flier JS. Clinical review 94: what's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 1998;83:1407-13.
122. Considine RV. Regulation of leptin production. Rev Endocr Metab Disord 2001;2:357-63.
123. Huscar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997;88:131-41.
124. Mountjoy KG, Mortrud MT, Low MJ, et al. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control segments of the brain. Mol Endocrinol 1994;8:1298-308.
125. Boston BA, Blaydon KM, Varnerin J, et al. Independent and additive effects of central POMC and leptin pathways on murine obesity. Science 1997;278:1641-4.
126. Seeley RJ, Yagaloff KA, Fisher SL, et al. Melanocortin receptors in leptin effects. Nature 1997;390:349.
127. Haynes WG, Morgan DA, Djalali A, et al. Activation of melanocortin-4 receptors enhances thermogenic sympathetic nerve activity to brown adipose tissue. Hypertension 1998;32:620.
128. Yeo GSH, Farooqi IS, Aminian S, et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998;20:111-2.
129. Vaisse C, Clement C, Guy-Grand B, et al. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 1998;20:113-4.
130. Schorr U, Blaschke K, Turan S, et al. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens 1998;16:1475-80.
131. Granger JP, West D, Scott J. Abnormal pressure natriuresis in the dog model of obesity-induced hypertension. Hypertension 1994;23:18-11.
132. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994;7:886-93.
133. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998;24:789-96.
134. Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999;60:401-5.
135. Licata G, Scaglione R, Ganguzza A, et al. Central obesity and hypertension: relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 1994;7:314-20.
136. Cooper R, McFarlane Anderson N, Bennett FI, et al. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 1997;11:107-11.
137. Cooper R, Forrester T, Ogunbiyi O, et al. Angiotensinogen levelsand obesity in four black populations. ICSHIB investigators. J Hypertens 1998;16:571-5.
138. Bloem LJ, Manatunga AK, Tewksbury DA, et al. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 1995;95:948-53.
139. Umemura S, Nyui N, Tamura K, et al. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997;10:629-33.
140. Uckaya G, Ozata M, Sonmez A, et al. Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm Metab Res 1999;31:435-8.
141. Giacchetti G, Faloia E, Sardu C, et al. Different gene expression of the RAS in human adipose tissue. Int J Obes Relat Metab Disord 1999;23:S71.
142. Frederich RC, Hamann A, Anderson S, et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995;1:950-3.
143. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270-7.
144. Massiera F, Seydoux J, Geloen A, et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001;142:5220-5.
145. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-70.
146. Gorzelniak K, Engeli S, Janke J, et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002;20:1115-20.
147. Nakao K, Ogawa Y, Suga S, et al. Molecular biology and biochemistry of the matriuretic peptide system. I. Natriuretic peptides. J Hypertens 1992;10:907-12.
148. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
149. Nakao K, Ogawa Y, Suga S, et al. Molecular biology and biochemistry of the natriuretic peptide system. I. Natriuretic peptide receptors. J Hypertens 1992;10:1111-4.
150. Melo LG, Veress AT, Chong CK, et al. Salt-sensitive hypertension in ANP knock out mice: potential role of abnormal plasma renin activity. Am J Physiol 1998;274:R255-61.
151. Melo LG, Steinhelper ME, Pang SC, et al. ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol Genomics 2000;3:45-58.
152. Dessi-Fulgheri P, Sarzani R, Tamburrini P, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 1997;15:1695-9.
153. Dessi-Fulgheri P, Sarzani R, Serenelli M, et al. Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Hypertension 1999;33:658-62.
154. Crandall DL, Ferraro GD, Cervoni P. Effect of experimental obesity and subsequent weight reduction upon circulating atrial natriuretic peptide. Proc Soc Exp Biol Med 1989;191:352-6.
155. Sarzani R, Dessi-Fulgheri P, Salvi F, et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 1999;17:1301-5.
156. Rocchini AP, Moorehead C, Katch V, et al. Forearm resistance vessel abnormalities and insulin resistance in obese adolescents. Hypertension 1992;19:615-20.
157. Zemel MB. Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin, resistance and hypertension. Mol Cell Biochem 1998;188:129-36.
158. Resnick LM, Militianu D, Cunnings AJ, et al. Direct magnetic resonance determination of aortic distensibility in essential hypertension, relation to age, abdominal visceral fat, and in situ intracellular free magnesium. Hypertension 1997;30:654-9.
159. Jacobs DB, Sowers JR, Hmeidan A, et al. Effects of weight reduction on cellular cation metabolism and vascular resistance. Hypertension 1993;21:308-14.
160. Frohlich ED, Epstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992;327:998-1008.
161. Simon G, Devereux RB, Roman MJ. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 1994;23:600-6.
162. Drenick EJ, Bale GS, Seltzer F, et al. Excessive mortality and cause of death in morbidly obese men. JAMA 1980;243:443-5.
163. Messerli FH, Sundgard-Riiske K, Reisin E, et al. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med 1983;99:757-61.
164. Smith HL, Willius FA. Adiposity of the heart a clinical pathologic study of 136 obese patients. Arch Intern Med 1933;52:910-31.
165. Lip GYH, Gammage MD, Beevers DG. Hypertension and the heart. Br Med Bull 1994;18:193-7.
166. Bharati S, Lev M. Cardiac conduction system involvement in sudden death of obese young people. Am Heart J 1995;129:273-81.
167. Basa S, Folliguet T, Anselmo M, et al. Lipomatous hypertrophy of the interatrial septum. Cardiovasc Surg 1994;2:229.
168. Duflou J, Virmani R, Rabin J, et al. Sudden death as a result of heart disease in morbid obesity. Am Heart J 1995;130:306-13.
169. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
170. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953-66.
171. Chu NF, Spiegelman D, Hotamisligil GS, et al. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease factors among men. Atherosclerosis 2001;157:495-503.
172. Alessai MC, Morange P, Juhan-Vague I. Fat cell function and fibrinolysis. Horm Metab Res 2000;32:504-8.
173. Rissanen P, Vahtera E, Krusius T, et al. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001;25:212-8.
174. Konstantinides S, Schafer K, Loskutoff DJ. The prothrombotic effects of leptin-possible implications for the risk of cardiovascular disease in obesity. Ann N Y Acad Sci 2001;947:134-41.
175. Bjorntorp P. Thrifty genes and human obesity. Are we chasing ghosts? Lancet 2001;358(9286):1006-8.
176. Dunn AL, Marcus BH, Kampert JB, et al. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA 1999;281:327-34.
177. Andersen RE, Wadden TA, Bartlett SJ, et al. Effects of lifestyle activity vs structured aerobic exercise in obese women: a randomized trial. JAMA 1999;281:335-40.
178. Institute of Medicine. Dietary reference intakes for energy, Carbohydrates, fibre, fat, fatty acids, cholesterol, and protein and amino acids. Food and Nutrition Board. Washington DC: National Academy Press; 2002.
179. Boutelle KN, Kirschenbaum DS. Further support for consistent self-monitoring as a vital component of successful weight control. Obes Res 1998;6(3):219-24.
180. Bruzzi I, Benigni A, Remuzzi G. Role of increased glomerular protein traffic in the progression of renal failure. Kidney Int 1997;62:529-32.
181. Rosenzweig A, Seidnan CE. Atrial natriuretic factor and related peptides hormones. Annu Rev Biochem 1991;60:229-55.
182. Maack T. Receptors of atrial natriuretic factor. Annu Rev Physiol 1992;54:11-27.
183. Dessi-Fulgeheri P, Sarzani R, Rappelli A. The natriuretic peptide system in obesity-related hypertension: new pathophysiology aspects. J Nephrol 1998;11:296-9.
184. Maoz E, Shamiss A, Peleg E, et al. The role of atrial natriuretic peptide in the natriuresis of fasting. J Hypertens 1992;10:1041-4.
185. Sarzani R, Paci MV, Dessi-Fulgheri P, et al. A comparative analysis of atrial natriuretic peptide receptor expression on rat tissue. J Hypertens 1993;11:S214-6.
186. Sarzani R, Dessi-Fulgheri P, Paci MV, et al. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996;19:581-5.
187. Lee GH, Proenca R, Montex JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996;379:632-5.
188. Mark AL, Correia M, Morgan DA, et al. Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertens 1999;33:537-41.
189. Golden P, MacCagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor: binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997;99:14-8.
190. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
191. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and Ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-61.
192. Pellymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in Ob/ob mice. Science 1995;269:540-3.
193. Nabro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002;162(18):2061-9.
194. Valsamakis G, Chetty RK, Kumar S. The management of obesity in type 2 diabetes mellitus. Curr Med Res Opin 2002;18:S75-81.
195. Laimer M, Ebenbichler CF, Kaser S, et al. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical Intervention. Int J Obes Relat Metab Disord 2002;26(5):659-62.
196. Torgerson JS, Sjostrom L. The Swedish Obese Subjects (SOS) study - rationale and results. Int J Obes Relat Metab Disord 2001;25:S2-4.
197. Sjostrom CD, Peltonem M, Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) intervention study. Obes Res 2001;9(3):188-95.